D
Douglas D. Ross
Researcher at University of Maryland Marlene and Stewart Greenebaum Cancer Center
Publications - 63
Citations - 5693
Douglas D. Ross is an academic researcher from University of Maryland Marlene and Stewart Greenebaum Cancer Center. The author has contributed to research in topics: Abcg2 & Multiple drug resistance. The author has an hindex of 31, co-authored 63 publications receiving 5405 citations. Previous affiliations of Douglas D. Ross include University of Maryland, Baltimore & Veterans Health Administration.
Papers
More filters
Journal ArticleDOI
A multidrug resistance transporter from human MCF-7 breast cancer cells
L. Austin Doyle,Weidong Yang,Lynne V. Abruzzo,Tammy Krogmann,Y. Gao,Arun K. Rishi,Douglas D. Ross,Douglas D. Ross +7 more
TL;DR: In this article, the authors identify a 2.4-kb mRNA that encodes a 663-aa member of the ATP-binding cassette superfamily of transporters that they termed breast cancer resistance protein (BCRP).
Journal ArticleDOI
The stem cell marker Bcrp/ABCG2 enhances hypoxic cell survival through interactions with heme.
Partha Krishnamurthy,Douglas D. Ross,Douglas D. Ross,Takeo Nakanishi,Kim Bailey-Dell,Sheng Zhou,Kelly E. Mercer,Balázs Sarkadi,Brian P. Sorrentino,John D. Schuetz +9 more
TL;DR: The studies demonstrate that the ABC transporter and marker of stem and progenitor cells known as the breast cancer resistance protein (BCRP or ABCG2) confers a strong survival advantage under hypoxic conditions and suggest that cells can, upon hypoxic demand, use BCRP to reduce heme or porphyrin accumulation, which can be detrimental to cells.
Journal ArticleDOI
Promoter characterization and genomic organization of the human breast cancer resistance protein (ATP-binding cassette transporter G2) gene
TL;DR: The BCRP gene is transcribed by a TATA-less promoter with several putative Sp1 sites, which are downstream from a putative CpG island, and the sequence 312 bp directly upstream from the B CRP transcriptional start site conferred basal promoter activity.
Journal ArticleDOI
Novel mechanisms of drug resistance in leukemia
TL;DR: Relatively high expression of BCRP mRNA is observed in approximately 30% of AML cases, suggesting a potential role for this new transporter in drug resistance in leukemia, and a novel ABC transporter, breast cancer resistance protein, was cloned and sequenced in the laboratory.
Journal Article
Estimation of cell survival by flow cytometric quantification of fluorescein diacetate/propidium iodide viable cell number.
Douglas D. Ross,Christopher C. Joneckis,Jose V. Ordonez,Allison M. Sisk,Richard K. Wu,Anne W. Hamburger,Richard E. Nora +6 more
TL;DR: The flow cytometric viability assay is facile, relatively rapid, and since it is ideal for studying cells in suspension culture, its potential as a predictor of chemotherapeutic response in leukemia warrants further evaluation.